Molecular and Cellular Basis of Viable Dysfunctional Myocardium-Reference-Cited by-同舟云学术

Molecular and Cellular Basis of Viable Dysfunctional Myocardium

Published:2014-07 Issue:4 Volume:7 Page:680-691
ISSN:1941-3289
Container-title:Circulation: Heart Failure
language:en
Short-container-title:Circ Heart Fail

Author:

Bayeva Marina¹,Sawicki Konrad Teodor¹,Butler Javed¹,Gheorghiade Mihai¹,Ardehali Hossein¹

Affiliation:

1. From the Division of Cardiology, Department of Medicine, Northwestern University School of Medicine, Chicago, IL (M.B., K.T.S., M.G., H.A.); and Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA (J.B.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference141 articles.

1. Heart Disease and Stroke Statistics—2012 Update

2. Epidemiology and Cost of Advanced Heart Failure

3. Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction11This study was carried out in the framework of the European Community (EC) Concerted Action on PET: Investigation of Cellular Regeneration and Degeneration.

4. Magnitude and Time Course of Changes Induced by Continuous-Flow Left Ventricular Assist Device Unloading in Chronic Heart Failure

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sanggenol L Reduces LPS-induced Myocardial Injury and Inflammation by Activating PI3K/AKT/mTOR and Inhibiting NF-κB in Rats;Pharmacognosy Magazine;2024-08-21

2. Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs;Stem Cell Research & Therapy;2024-06-13

3. Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers;Biomedicines;2024-05-09

4. Tangeretin, An Active Flavonoid in Citrus Peel, Alleviates Cisplatin-Induced Cardiotoxicity via the Activation of AMPK and the Prevention on Mitochondrial Dysfunction;2024-01-18

5. Medical Decision-Making and Revascularization in Ischemic Cardiomyopathy;Medical Clinics of North America;2023-12